Marc K. Hellerstein
YOU?
Author Swipe
View article: Supplementary Table 1 from Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer
Supplementary Table 1 from Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer Open
Supplementary Table 1. The Comparisons of Patient Characteristics in All (N = 178), CT (N = 170), DXA (N = 162), and D3Cr (N = 118) Groups
View article: Supplementary Table 2 from Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer
Supplementary Table 2 from Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer Open
Supplementary Table 2. Sex-Specific Standard Deviations of Body Composition Measurements (CT SMA, DXA ALM, D3Cr Muscle, CT TAT, and DXA TBF)
View article: Supplementary Table 5 from Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer
Supplementary Table 5 from Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer Open
Supplementary Table 5. The Adjusted Associations of Body Composition Measurements (Per SD Increase) with Reduced RDI Counting from the Initiation of First Chemotherapy
View article: Supplementary Table 6 from Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer
Supplementary Table 6 from Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer Open
Supplementary Table 6. Sex-Specific Adjusted Associations of Body Composition Measurements (Per SD Increase) with Reduced RDI and Relative Changes (%) in the Number of Moderate and Severe Adverse Events
View article: Supplementary Table 4 from Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer
Supplementary Table 4 from Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer Open
Supplementary Table 4. The Adjusted Associations of Body Composition Measurements (Per SD Increase) with Reduced RDI Counting for Each Chemotherapy Agent
View article: Effects of inhibition of Janus kinase signalling during controlled mechanical ventilation on the rate of skeletal muscle protein synthesis
Effects of inhibition of Janus kinase signalling during controlled mechanical ventilation on the rate of skeletal muscle protein synthesis Open
We employed a unique murine intensive care unit (ICU) model allowing long‐term studies of the ICU condition (immobilization, paralysis, sedation and mechanical ventilation). This model resulted in a substantial loss of myofibrillar protein…
View article: Nutrient-Sensing Nuclear Receptor <i>PPARα</i> Controls Liver Proteostasis
Nutrient-Sensing Nuclear Receptor <i>PPARα</i> Controls Liver Proteostasis Open
Peroxisome proliferator-activated receptor alpha ( PPARα ) is a nuclear receptor that orchestrates metabolic adaptation to fasting by regulating hepatic lipid and glucose metabolism. While these functions are well established, its role in …
View article: Skeletal Muscle Mass Measured Noninvasively by D3-Creatine Dilution in Children and Term Infants
Skeletal Muscle Mass Measured Noninvasively by D3-Creatine Dilution in Children and Term Infants Open
View article: Change in D3Cr muscle mass in oldest old men and its association with changes in grip strength and walking speed
Change in D3Cr muscle mass in oldest old men and its association with changes in grip strength and walking speed Open
Background The use of lean soft tissue (LST) mass as a surrogate measurement of skeletal muscle mass (SMM) has led to the conclusion that muscle loss is poorly related to functional decline. We hypothesized that when using a more accurate …
View article: Metabolic labeling kinetics of brain-derived 24S-hydroxycholesterol in blood in multiple sclerosis: Effects of treatment with the remyelinating antibody rHIgM22
Metabolic labeling kinetics of brain-derived 24S-hydroxycholesterol in blood in multiple sclerosis: Effects of treatment with the remyelinating antibody rHIgM22 Open
Background Cholesterol is an essential and major component of myelin. Brain cholesterol turnover in humans can be studied noninvasively by metabolic labeling of the brain-specific cholesterol metabolite, 24S-hydroxycholesterol (24-OHC), wh…
View article: Adipocyte lipin 1 expression associates with human metabolic health and regulates systemic metabolism in mice
Adipocyte lipin 1 expression associates with human metabolic health and regulates systemic metabolism in mice Open
Dysfunctional adipose tissue is believed to promote the development of hepatic steatosis and systemic insulin resistance, but many of the mechanisms involved are still unclear. Lipin 1 catalyzes the conversion of phosphatidic acid to diacy…
View article: Supplementary Table 2 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer
Supplementary Table 2 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer Open
Supplementary Table 2. Sex-Specific Standard Deviations of Body Composition Measurements (CT SMA, DXA ALM, D3Cr Muscle, CT TAT, and DXA TBF)
View article: Supplementary Table 2 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer
Supplementary Table 2 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer Open
Supplementary Table 2. Sex-Specific Standard Deviations of Body Composition Measurements (CT SMA, DXA ALM, D3Cr Muscle, CT TAT, and DXA TBF)
View article: Supplementary Table 5 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer
Supplementary Table 5 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer Open
Supplementary Table 5. The Adjusted Associations of Body Composition Measurements (Per SD Increase) with Reduced RDI Counting from the Initiation of First Chemotherapy
View article: Supplementary Table 5 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer
Supplementary Table 5 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer Open
Supplementary Table 5. The Adjusted Associations of Body Composition Measurements (Per SD Increase) with Reduced RDI Counting from the Initiation of First Chemotherapy
View article: Supplementary Table 1 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer
Supplementary Table 1 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer Open
Supplementary Table 1. The Comparisons of Patient Characteristics in All (N = 178), CT (N = 170), DXA (N = 162), and D3Cr (N = 118) Groups
View article: Supplementary Table 6 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer
Supplementary Table 6 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer Open
Supplementary Table 6. Sex-Specific Adjusted Associations of Body Composition Measurements (Per SD Increase) with Reduced RDI and Relative Changes (%) in the Number of Moderate and Severe Adverse Events
View article: Data from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer
Data from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer Open
Background: Despite evidence that low muscle increases the risk of chemotoxicity, most chemotherapies are dosed on body surface area without considering body composition. Among 178 patients with colon cancer, we assessed muscle and adipose…
View article: Supplementary Table 4 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer
Supplementary Table 4 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer Open
Supplementary Table 4. The Adjusted Associations of Body Composition Measurements (Per SD Increase) with Reduced RDI Counting for Each Chemotherapy Agent
View article: Supplementary Table 3 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer
Supplementary Table 3 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer Open
Supplementary Table 3. The Adjusted Associations of Scaled Body Composition Measurements (Per SD Increase) with Reduced RDI and Relative Changes (%) in the Number of Moderate and Severe Adverse Events
View article: Supplementary Table 3 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer
Supplementary Table 3 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer Open
Supplementary Table 3. The Adjusted Associations of Scaled Body Composition Measurements (Per SD Increase) with Reduced RDI and Relative Changes (%) in the Number of Moderate and Severe Adverse Events
View article: Supplementary Table 1 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer
Supplementary Table 1 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer Open
Supplementary Table 1. The Comparisons of Patient Characteristics in All (N = 178), CT (N = 170), DXA (N = 162), and D3Cr (N = 118) Groups
View article: Supplementary Table 4 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer
Supplementary Table 4 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer Open
Supplementary Table 4. The Adjusted Associations of Body Composition Measurements (Per SD Increase) with Reduced RDI Counting for Each Chemotherapy Agent
View article: Supplementary Table 6 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer
Supplementary Table 6 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer Open
Supplementary Table 6. Sex-Specific Adjusted Associations of Body Composition Measurements (Per SD Increase) with Reduced RDI and Relative Changes (%) in the Number of Moderate and Severe Adverse Events
View article: Reductions in functional muscle mass and ability to ambulate in Duchenne muscular dystrophy from ages 4 to 24 years
Reductions in functional muscle mass and ability to ambulate in Duchenne muscular dystrophy from ages 4 to 24 years Open
Duchenne muscular dystrophy (DMD) results in a progressive loss of functional skeletal muscle mass (MM) and replacement with fibrofatty tissue. Accurate evaluation of MM in DMD patients has not previously been available. Our objective was …
View article: Changes in protein fluxes in skeletal muscle during sequential stages of muscle regeneration after acute injury in male mice
Changes in protein fluxes in skeletal muscle during sequential stages of muscle regeneration after acute injury in male mice Open
Changes in protein turnover play an important role in dynamic physiological processes, including skeletal muscle regeneration, which occurs as an essential part of tissue repair after injury. The inability of muscle tissue to recapitulate …
View article: Data from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma
Data from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma Open
Altered lipid metabolism is a common hallmark of various cancers, including intrahepatic cholangiocarcinoma (ICC), a highly lethal carcinoma that lacks effective treatment options. To elucidate the lipid metabolism changes in ICC, we coupl…
View article: Supplementary Table 1 from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma
Supplementary Table 1 from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma Open
The comprehensive information about all detected lipids
View article: Supplementary Table 1 from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma
Supplementary Table 1 from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma Open
The comprehensive information about all detected lipids
View article: Data from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma
Data from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma Open
Altered lipid metabolism is a common hallmark of various cancers, including intrahepatic cholangiocarcinoma (ICC), a highly lethal carcinoma that lacks effective treatment options. To elucidate the lipid metabolism changes in ICC, we coupl…